To view this email as a web page, click here.
 
Four therapeutic areas to watch in 2018
Find out the top therapeutic areas in 2018.
Read more
ADVERTISEMENT
 
FDA okays short-acting, follow-on insulin for diabetes
FDA approved the first short-acting insulin approved as a "follow-on" product.
Why it's unique
 
New cancer biosimilar could net major sales
A new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in United States sales last year, is expected to produce blockbuster sales.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.